The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis C Lifestyle: Peaches Are a Great Summer Snack

Back to News Homepage

Next

Medical Update: New Perspective on Marijuana for Hepatitis C

Older Patients Have a Better Outcome with TVR-Based Triple Therapy

August 1, 2013

Print this page

Although it has been determined that age has no impact on the outcome of triple therapy with pegylated interferon, ribavirin and telaprevir, older patients benefit more than with the traditional dual therapy.

Telaprevir safe, effective among older patients with chronic HCV

Furusyo N. J Hepatol. 2013;59:205-212.

July 30, 2013

Advanced age did not impact the efficacy of triple therapy with pegylated interferon, ribavirin and telaprevir among patients with hepatitis C genotype 1b in a recent study.

In a prospective study, researchers evaluated 120 patients with chronic hepatitis C genotype 1b, including 64 participants aged older than 60 years. All patients received peginterferon alfa-2b, ribavirin and telaprevir for 12 weeks, then 12 weeks of peginterferon and ribavirin. During prior therapy 53.3% of participants had relapsed, 22.5% were treatment-naive, 20.8% were prior nonresponders and 3.3% had an unknown prior response.

Continue reading this entire article:
http://www.healio.com/infectious-disease/hepatitis-resource-center-2013/telaprevir-safe-effective-among-older-patients-with-chronic-hcv

No Comments - be the first!
Share
Share

Previous

Hepatitis C Lifestyle: Peaches Are a Great Summer Snack

Back to News Homepage

Next

Medical Update: New Perspective on Marijuana for Hepatitis C

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.